Tiago Abreu-Mota

Tiago Abreu-Mota

Auto-generated profile, based on publicly available information

Tiago Abreu-Mota

Department of Biomedicine – Haus Petersplatz, Division of Experimental Virology, University of Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
TATiago Abreu-Mota
Tiago Abreu-Mota
KHKatie R. Hagen
Katie R. Hagen
KCKurt Cooper
Kurt Cooper
PJPeter B. Jahrling
Peter B. Jahrling
GTGene Tan
Gene Tan
MSMatthias Schnell
Matthias Schnell
Lassa fever (LF), caused by Lassa virus (LASV), is a viral hemorrhagic fever for which no approved vaccine or potent antiviral treatment is available. LF is a WHO priority disease and, together with rabies, a major health burden in West Africa. Here we present the development and characterization of an inactivated recombinant LASV and rabies vaccine candidate (LASSARAB) that expresses a codon-optimized LASV glycoprotein (coGPC) and is adjuvanted by a TLR-4 agonist (GLA-SE). LASSARAB elicits lasting humoral response against LASV and RABV in both mouse and guinea pig models, and it protects both guinea pigs and mice against LF. We also demonstrate a previously unexplored role for non-neutralizing LASV GPC-specific antibodies as a major mechanism of protection by LASSARAB against LF through antibody-dependent cellular functions. Overall, these findings demonstrate an effective inactivated LF vaccine and elucidate a novel humoral correlate of protection for LF.

15 March 2019 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
RKRohan Keshwara
Rohan Keshwara
KHKatie R Hagen
Katie R Hagen
TATiago Abreu-Mota
Tiago Abreu-Mota
APAmy B Papaneri
Amy B Papaneri
DLDavid Liu
David Liu
MSMatthias Schnell
Matthias Schnell
Marburg virus (MARV) is a filovirus related to Ebola virus (EBOV) associated with human hemorrhagic disease. Outbreaks are sporadic and severe with a reported case mortality rate upward of 88%. There is currently no antiviral or vaccine available. Given the sporadic nature of outbreaks, vaccines provide the best approach for long-term control of MARV in endemic regions. We have developed an inactivated rabies virus-vectored MARV vaccine (FILORAB3) to protect against Marburg virus disease. Immunogenicity studies in our lab have shown that a Th1-biased seroconversion to both RABV and MARV glycoproteins is beneficial for protection in a preclinical murine model. As such, we adjuvanted FILORAB3 with GLA-SE, a TLR-4 agonist. Across two different BALB/c mouse challenge models, we achieved 92% protection against murine-adapted Marburg virus (ma-MARV). Although our vaccine elicited strong MARV GP antibodies, it did not strongly induce neutralizing antibodies. Through both in vitro and in vivo approaches, we elucidated a critical role for NK cell-dependent antibody-mediated cellular cytotoxicity (ADCC) in vaccine-induced protection. Overall, these findings demonstrated that FILORAB3 is a promising vaccine candidate for Marburg virus disease. IMPORTANCE Marburg virus (MARV) is a virus similar to Ebola virus and also causes a hemorrhagic disease, which is highly lethal. In contrast to EBOV, only a few vaccines are developed against MARV and researcher do not understand what kind of immune responses are required to protect from MARV. Here we show that antibodies directed against MARV after application of our vaccine protect in an animal system but fail to neutralize the Virus in widely used virus neutralization assay against MARV. This newly discovered activity needs to be more considered when analyzing MARV vaccines or infections.

3 August 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
DKDRISHYA B KURUP
DRISHYA B KURUP
CFChristine R Fisher
Christine R Fisher
TSTodd G Smith
Todd G Smith
TATiago Abreu-Mota
Tiago Abreu-Mota
YYYong Yang
Yong Yang
MSMatthias J Schnell
Matthias J Schnell
Background: Ebola virus (EBOV) is a highly lethal member of the Filoviridae family associated with human hemorrhagic disease. Despite being a sporadic disease, it caused a large outbreak in 2014–2016 in West Africa and another outbreak recently in the Democratic Republic of Congo. Several vaccine candidates are currently in preclinical and clinical studies but none are stable without cold chain storage.Methods: We used preservation by vaporization (PBV), a novel processing technology to heat-stabilize FiloRab1 (inactivated rabies-based Ebola vaccine), a candidate Ebola vaccine, and stored the vials at temperatures ranging from 4°C to 50°C for 10 days to 12 months. We immunized Syrian hamsters with the best long-term stable FiloRab1 PBV vaccines and challenged them with rabies virus (RABV).Results: Syrian hamsters immunized with FiloRab1 PBV–processed vaccines stored at temperatures of 4°C and 37°C for 6 months, and at 50°C for 2 weeks, seroconverted against both RABV-G and EBOV-GP. Notably, all of the FiloRab1 PBV vaccines proved to be 100% effective in a RABV challenge model.Conclusions: We successfully demonstrated that the FiloRab1 PBV vaccines are stable and efficacious for up to 6 months when stored at temperatures ranging from 4°C to 37°C and for up to 2 weeks at 50°C.

11 April 2013 in Journal of Nanoparticle Research
Verified
Journal Article
Closed access
PDF file
MPMarta Pojo
Marta Pojo
SCSusana R. Cerqueira
Susana R. Cerqueira
TMT. Mota
T. Mota
AXA. Xavier-Magalhães
A. Xavier-Magalhães
SRS. Ribeiro-Samy
S. Ribeiro-Samy
António SalgadoAntónio Salgado
António Salgado

6 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
TATiago Abreu-Mota
Tiago Abreu-Mota
AMAnna-Friederike Marx
Anna-Friederike Marx
DWDorothee Winterberg
Dorothee Winterberg
KTKaren Tintignac
Karen Tintignac
JFJonas Fixemer
Jonas Fixemer
DPDaniel Pinschewer
Daniel Pinschewer
Lassa fever, a viral hemorrhagic fever caused by the arenavirus Lassa virus (LASV), affects thousands of individuals annually, highlighting the need for a vaccine. Yet, immunological correlates of viral load control remain poorly defined. Here we study vaccination-induced immunity in a surrogate LASV challenge model in mice. We find that LASV-cross-reactive B cell immunity induced by the glycoprotein of distantly related arenaviruses, such as lymphocytic choriomeningitis virus (LCMV), provides significant viral load control. Counter to common concepts, suppression of viremia is observed in the absence of CD8 T cells or neutralizing antibodies but correlates with non-neutralizing glycoprotein-specific antibody responses. Adoptive cell transfer experiments with monoclonal LCMV-specific B cells demonstrates that these cells suppress viral loads when previously activated by a heterologous cross-reactive glycoprotein and diversified by somatic hypermutation. These findings establish vaccination-induced B cell immunity to the LASV glycoprotein as a correlate of viral load control, independently of virus-neutralizing antibody titers at the time of challenge.